Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for InMed Pharmaceuticals Inc. (INM : NSDQ)

• Company Description    InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $1.60 Daily Weekly Monthly 20 Day Moving Average: 65,947 shares Shares Outstanding: 2.80 (millions) Market Capitalization: $4.49 (millions) Beta: 0.29 52 Week High: $6.40 52 Week Low: $1.56 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -24.64% -26.61% 12 Week -31.03% -33.89% Year To Date -66.25% -70.50%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1445 885 West Georgia St. - VANCOUVER,A1 V6C 3E8 CAN ph: 604-669-7207 fax: - ir@inmedpharma.com http://www.inmedpharma.com

• General Corporate Information    Officers Eric A. Adams - Chief Executive Officer; President and Director Netta Jagpal - Chief Financial Officer Andrew Hull - Chairman and Director Bryan Baldasare - Director Nicole Lemerond - Director Peer Information InMed Pharmaceuticals Inc. (GSAC) InMed Pharmaceuticals Inc. (CASI) InMed Pharmaceuticals Inc. (ALCD.) InMed Pharmaceuticals Inc. (OMNN) InMed Pharmaceuticals Inc. (CGPI.) InMed Pharmaceuticals Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 457637700 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/11/26 Share - Related Items Shares Outstanding: 2.80 Most Recent Split Date: 11.00 (0.05:1) Beta: 0.29 Market Capitalization: $4.49 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.39 Price/Cash Flow: - Price / Sales: 0.94 EPS Growth vs. Year Ago Period: 83.76% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -11.46% vs. Previous Quarter: -14.11% ROE 09/30/25 - -85.91 06/30/25 - -93.19 03/31/25 - -107.93 ROA 09/30/25 - -70.29 06/30/25 - -74.49 03/31/25 - -82.97 Current Ratio 09/30/25 - 6.95 06/30/25 - 6.99 03/31/25 - 3.49 Quick Ratio 09/30/25 - 6.37 06/30/25 - 6.47 03/31/25 - 3.04 Operating Margin 09/30/25 - -171.13 06/30/25 - -165.12 03/31/25 - -168.87 Net Margin 09/30/25 - -171.13 06/30/25 - -165.12 03/31/25 - -168.87 Pre-Tax Margin 09/30/25 - -171.13 06/30/25 - -165.12 03/31/25 - -168.71 Book Value 09/30/25 - 4.13 06/30/25 - 6.71 03/31/25 - 5.82 Inventory Turnover 09/30/25 - 3.38 06/30/25 - 3.16 03/31/25 - 3.04 Debt-to-Equity 09/30/25 - 0.02 06/30/25 - 0.02 03/31/25 - 0.06 Debt-to-Capital 09/30/25 - 1.82 06/30/25 - 2.23 03/31/25 - 5.63

Powered by Zacks Investment Research ©